The Blueprint of Event-Driven Pharmacology: Overcoming CMC and Pharmacokinetic Hurdles in bRo5 Targeted Protein Degraders

shift from traditional, occupancy-driven kinase inhibitors to event-driven Targeted Protein Degraders (PROTACs). It examines the complex molecular architecture of bivalent matchmakers and addresses how their required trifunctional geometry inherently violates traditional parameters for oral bioavailability, pushing them into the Beyond Rule of Five (bRo5) space. To overcome these physicochemical liabilities, the dossier details advanced formulation and analytical strategies, including: ****** Utilizing Exposed Polar Surface Area (EPSA) rather than TPSA to accurately quantify passive membrane permeability in flexible molecules. ****** Engineering Amorphous Solid Dispersions (ASDs) and leveraging slurry conversions to bypass the solid-state dissolution bottleneck. ****** Deploying high-throughput LC-MS/MS platforms to track intracellular catalytic activity and ternary complex formation at sub-nanogram limits of quantification.